ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

9777	Companies
195686	Keywords
126721	Articles
104053	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

BRIEF

published on 08/20/2025 at 18:05, 5 months 10 days ago

OSE Immunotherapeutics Appoints Thomas Gidoin as CFO

Chief Financial Officer Strategic Planning Biotech Financing OSE Immunotherapeutics Thomas Gidoin
PRESS RELEASE

published on 08/20/2025 at 18:00, 5 months 10 days ago

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
OSE Immunotherapeutics appoints Thomas Gidoin as Chief Financial Officer, bringing deep expertise in capital markets and financial strategy to the company. Gidoin succeeds Anne-Laure Autret-Cornet

Chief Financial Officer Capital Markets Financial Strategy OSE Immunotherapeutics Thomas Gidoin
BRIEF

published on 07/02/2025 at 08:05, 6 months 28 days ago

OSE Immunotherapeutics Updates on Legal Proceedings

Transparency Shareholder Meeting Legal Proceedings OSE Immunotherapeutics Nantes Commercial Court
PRESS RELEASE

published on 07/02/2025 at 08:00, 6 months 28 days ago

OSE Immunotherapeutics met à jour l’information sur les procédures en cours
OSE Immunotherapeutics provides an update on ongoing legal proceedings regarding shareholders' motions, confirms plans for annual shareholders' meeting on September 30, 2025

Shareholders Biotech Annual Meeting Legal Proceedings OSE Immunotherapeutics
BRIEF

published on 06/20/2025 at 19:35, 7 months 10 days ago

OSE Immunotherapeutics secures its General Meeting

Shareholders Transparency General Assembly Legal Proceedings OSE Immunotherapeutics
PRESS RELEASE

published on 06/20/2025 at 19:30, 7 months 10 days ago

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
OSE Immunotherapeutics reaffirms commitment to transparent and serene General Meeting in compliance with market rules, providing 'Questions and Answers' document for shareholders

Shareholders Transparency General Meeting OSE Immunotherapeutics Market Rules
BRIEF

published on 06/19/2025 at 15:58, 7 months 11 days ago

Strategic change within OSE Immunotherapeutics

Board Of Directors General Meeting Crossing Thresholds OSE Immunotherapeutics Shareholders' Agreement
BRIEF

published on 04/30/2025 at 07:35, 9 months ago

OSE Immunotherapeutics Presents New Gene Expression Signature at AACR 2025

Immuno-oncology Personalized Treatment Immune Checkpoint Blockade Gene Expression Signature Cancer Prediction
PRESS RELEASE

published on 04/30/2025 at 07:30, 9 months ago

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
OSE Immunotherapeutics and Léon Bérard Cancer Center present a new gene expression signature for predicting clinical response to immune checkpoint at AACR Annual Meeting 2025

AACR Annual Meeting OSE Immunotherapeutics Gene Expression Signature Léon Bérard Cancer Center Clinical Response Prediction
BRIEF

published on 04/09/2025 at 07:35, 9 months 21 days ago

OSE Immunotherapeutics to Present Data on Lusvertikimab at DDW 2025

Ulcerative Colitis OSE Immunotherapeutics Lusvertikimab Phase 2 Extension DDW 2025

Accesswire

Published on 01/30/2026 at 14:00, 7 hours 51 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 13 hours 16 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 13 hours 51 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 19 hours 36 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 21 hours 51 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

EQS Group

Published on 01/30/2026 at 20:10, 1 hour 40 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 1 hour 41 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 1 hour 43 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 19:13, 2 hours 37 minutes ago

Total Voting Rights
Published on 01/30/2026 at 18:31, 3 hours 19 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 01/30/2026 at 17:45, 4 hours 6 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 13 hours 51 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 3 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 4 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 4 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE